A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants

• Autoinjector (Combination product): Navenibart administered subcutaneously via autoinjector
• Vial and syringe (Drug): Navenibart administered subcutaneously via vial and syringe

Primary outcomes

• Maximum concentration (Cmax) following a single dose of subcutaneous navenibart [Up to 84 days post dose]: Plasma concentrations are assessed via a validated method and used to estimate PK parameters via noncompartmental analysis.
• Area under the concentration versus time curve from time 0 to 84 days (AUC0-84d) following a single dose of subcutaneous navenibart [Up to 84 days post dose]: Plasma concentrations are assessed via a validated method and used to estimate PK parameters via noncompartmental analysis.

Secondary outcomes

• Time to reach maximum plasma concentration (Tmax) following a single dose of subcutaneous navenibart [Up to 140 days post dose]: Plasma concentrations are assessed via a validated method and used to estimate PK parameters via noncompartmental analysis.
• Apparent clearance (CL/F) following a single dose of subcutaneous navenibart [Up to 140 days post dose]: Plasma concentrations are assessed via a validated method and used to estimate PK parameters via noncompartmental analysis.
• Apparent volume of distribution during the terminal phase (Vz/F) following a single subcutaneous dose of navenibart [Up to 140 days post dose]: Plasma concentrations are assessed via a validated method and used to estimate PK parameters via noncompartmental analysis.
• Terminal half-life (t1/2) following a single subcutaneous dose of navenibart [Up to 140 days post dose]: Plasma concentrations are assessed via a validated method and used to estimate PK parameters via noncompartmental analysis.
• Incidence of treatment-emergent adverse events (TEAEs), including severity and relationship to navenibart following a single subcutaneous dose of navenibart [Up to 168 days post dose]: Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), Version 28.0 or higher. All AEs will be assigned a severity grade using CTCAE Version 6.0 or higher. Relationship to navenibart will be assessed by the investigator.
• Incidence and magnitude of treatment-emergent anti-drug antibodies (ADA) [Up to 140 days post dose]: ADA will be assessed via a validated bioanalytical method. Incidence will be assessed as proportion of participants with a treatment-emergent ADA. Magnitude of ADA response will be assessed via titers for confirmed ADA-positive samples.

Sex: All, ages: 18 Years to 55 Years, accepts healthy volunteers

Key Inclusion Criteria:

* Males and females 18 to 55 years of age
* In good health, as determined by the Investigator
* Written informed consent, including confirmation of willingness to comply with all trial procedures
* Body weight between 50 and 100 kg, and body mass index (BMI) between 18 and 30 kg/m\^2
* Has not previously received navenibart
* Not pregnant or breastfeeding and agreement to comply with requirements for pregnancy and breastfeeding, contraception use, and egg donation for the specified periods.

Key Exclusion Criteria:

* Prior or ongoing medical history, or results of a medical assessment, that the Investigator feels could result in a risk to the safety of the participant or the quality of data from the trial.
* Key laboratory results outside of defined ranges
* History or positive test results for tobacco, nicotine products, alcohol, marijuana (cannabis), or drugs of abuse
* Receipt of other prohibited medications, biologic medications, or investigational products within defined windows prior to dosing
* History of severe allergic reactions with an unknown cause
* Donation of blood (at least 500 mL), or any amount of platelets or plasma within defined windows prior to dosing.
* Known hypersensitivity to any component of navenibart
* Any condition that the Investigator feels may affect the ability to provide written informed consent or demonstrates unwillingness or inability to comply with trial procedures